Purpose. Results of a study to determine demographic and clinical characteristics predictive of oversedation and potential opioid-induced respiratory depression (OIRD) in hospitalized patients are reported.
P
ain is a universal symptom experienced by up to 84% of hospitalized patients. 1 Opioids are a mainstay of treatment for moderate-to-severe pain in both surgical and nonsurgical patients due to the intensity of pain experienced with surgery, diagnostic procedures, and underlying chronic and/or malignant conditions. While the benefits of opioids often outweigh the risks, adverse effects should be recognized, as they range from common and innocuous (e.g., constipation, pruritus) to rare and potentially life-threatening (e.g., respiratory depression). Complications from opioid therapy can lead to patient harm, poor clinical outcomes, and increased costs. 2, 3 While the rate of opioid-induced respiratory depression (OIRD), as measured by naloxone administration in the postoperative setting, is less than 1% among hospitalized patients treated with opioids, OIRD events still pose a grave patient safety risk. [4] [5] [6] [7] The seriousness of these events called the Joint Commission to action in August 2012, when it released a sentinel event alert describing the problems of OIRD and oversedation in hospitalized patients. 8 The most common types of
• Opioid-induced respiratory depression (OIRD) and oversedation are significant threats to hospitalized patients.
• Risk factors for OIRD and oversedation identified via regression modeling include female sex, comorbid renal disease, untreated sleep apnea, and certain opioid types and routes of administration.
• Organizations can develop quality-improvement tools to prevent oversedation and safeguard patients.
opioid-related events reported to the Joint Commission were wrong-dose medication errors, followed by improper patient monitoring, excessive dosing, medication interactions, and adverse drug reactions. Although excessive dosing is considered a potential harbinger of OIRD and oversedation, mounting evidence indicates that individual and clinical factors may place some patients at higher risk for OIRD and oversedation. A compendium of 105 cases reported in the literature revealed that naloxone administration in the acute care setting was more likely in women; in 30-40% of these cases, patients had sleep apnea, renal impairment, obesity, pulmonary disease, neurological disorders, or genetic polymorphisms. For example, not all patients metabolize medications at the same rate, and patients may be genetically deficient in key isozymes needed for metabolization. 9 Additional contributing factors associated with a high prevalence of oversedation include being very young or elderly; opioid naivety; recent surgery, especially thoracic or upper abdominal surgery; longer duration of anesthesia; preexisting pulmonary or cardiac disease or other major organ failure; and concurrent use of other central nervous system (CNS) and respiratory depressant medications. 8, 10 These factors all contribute to the variability observed in opioid effectiveness and safety. 11 All studies suggesting these risks were descriptive and lacked controls.
Only 1 study found in the literature used a control group of patients who were not sedated and were compared with oversedated patients. 12 In that study, investigators explored a hospital database of naloxone administration at a community hospital. They determined that patients who received the reversal agent had an average of 5 risk factors for OIRD and oversedation, as compared with an average of 3 risk factors in the control group. Identified significant predictors of naloxone use were comorbid renal disease, cardiac disease, respiratory disease, concurrent use of sedating medications, and positive smoking status.
Prescribing behaviors, opioid administration practices, and patient monitoring can additionally play a role in OIRD and oversedation. In an analysis of the Anesthesia Closed Claims Project database, Lee and colleagues 13 found that 3 factors (multiple prescribers, concurrent administration of sedating medications, and inadequate nurse assessment and response) contributed heavily to OIRD, and 97% of cases were judged as preventable. Evidence-based quality-improvement efforts are essential to improve safety for hospitalized patients.
A thorough understanding of the predictive characteristics of OIRD and sedation is critical considering the frequency of opioid use in hospitalized patients and potential for significant patient harm. A reliable prognostic model is needed. The purpose of the study described here was to determine whether individual patient characteristics, clinical characteristics, comorbidity characteristics, opioid-related factors, and use or concurrent use of potentially sedating medications can reliably predict OIRD and oversedation in hospitalized patients receiving opioids.
Methods
Study population. In our retrospective case-control study, the case sample consisted of patients entered into an oversedation database, a quality-improvement tool used at a 304-bed community teaching hospital in the northwestern United States. Electronic health records (EHRs) of patients entered into the database were then screened for all of the following inclusion criteria: (1) inpatient status when oversedation and OIRD occurred, (2) a sedation score of ≥3 on the Sedation-Agitation Scale (SAS), 14 a validated 7-point sedation scale (1 = unarousable, 3 = sedation, 7 = dangerous agitation), and/or respiratory depression (0 = needs respiratory assistance, 2 = regular, easy, good expansion breathing), and (3) receipt of an opioid reversal medication that elicited a response. An increase in respirations or improved consciousness by at least 1 level on the SAS scale was considered a positive response to the reversal agent. Patients excluded from the study were those who (1) did not receive opioids on a nursing unit, (2) received the reversal medication (naloxone) in the emergency department, in surgery, or on the postanesthesia unit, or (3) received moderate sedation for a procedure (e.g., in an endoscopy suite). Cases involving medication errors were also excluded by consensus of the investigators; most of these errors involved hydromorphone ordered at a high dose. A control group was randomly selected from among the patients who received opioids but did not experience oversedation. A 2:1 allocation of controls allowed for a better comparison that would reflect the overall hospitalized population. Controls were not matched because of the predictive design of the study. The study was approved by the Institutional Review Board of Billings.
Data collection. Investigators screened the most recent oversedation incidents and then selected cases in reverse chronological order until the desired sample size was achieved. A team of 3 or 4 investigators met weekly to determine the eligibility of patients newly reported to the oversedation database for inclusion in the study sample. The team reviewed information on oversedation events, including physician and nurse notes, vital signs, and medications administered prior to the event. Patients were excluded if the oversedation was possibly due to nonopioid factors. For example, some patients were found to have sedation related to sepsis and were excluded from the study sample.
EHR data collected included 4 demographic variables (age, sex, race, and marital status), 2 clinical characteristics (body mass index [BMI] and reason for admission), 3 disease characteristics (lung disease [chronic obstructive pulmonary disease, interstitial pneumonitis, lung cancer, and pulmonary fibrosis], comorbid renal disease [defined as a serum creatinine concentration of >1.5 mg/dL and a glomerular filtration rate of <60 mL/ min per 1.73 m 2 of body surface area], and sleep apnea), and the following medication-related variables: opioid tolerance prior to hospitalization (defined as use of ≥60 milligram morphine equivalents [MME] daily over the past 2 weeks) 15 and type of opioid administered (i.e., morphine, oxycodone, hydromorphone, fentanyl, or hydrocodone). Additionally, concurrent use of the following potentially sedating medications was noted: acetylcholinesterase inhibitors, anticonvulsants, monoamine oxidase inhibitor antidepressants, serotonin and norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, tricyclic antidepressants, other miscellaneous antidepressants, antihistamines, antitussives, nonbenzodiazepine hypnotics, benzodiazepines, barbiturates, alcohol, muscle relaxants, phenothiazines and their derivatives (only when used in combination with opioids), and typical and atypical antipsychotics.
To enumerate the potential for oversedation associated with various medications, a risk scoring tool based on mean half-life values for medications given prior to oversedation events was developed. Medications were divided into 2 categories: (1) agents that can cause sedation only and (2) agents that can cause respiratory depression as well as sedation. For sedating medications, 1 point was assigned for each medication administered to a patient in the study sample at an interval less than the drug's half-life; 0.5 point was assigned for administration at an interval of ≥1 but less than 2 half-lives. For medications with the potential to cause both sedation and respiratory depression, 2 points were assigned for each administration at an interval of <1 half-life and 1 point for each administration at an interval of ≥1 but less than 2 halflives. This scoring process was employed for the oversedation cases to control for pharmacologic interventions other than OIRD that could have influenced an oversedation event. These data were examined descriptively (data not shown). Because the control cases lacked an oversedation event, a separate risk scoring system (1 point for each administered medication that could potentially cause sedation, and 2 points for each administered medication with the potential to cause respiratory depression and sedation during the hospital stay) was employed in analyzing both control and oversedation cases in order to allow between-group comparisons of medication-use factors potentially associated with oversedation and OIRD risk. These comparisons were used in the risk model.
Statistical analysis. Binary logistic regression was used to determine predictors of oversedation and OIRD. Occurrence versus nonoccurrence of oversedation was the dependent variable. Analyses were conducted using the statistical packages SPSS, version 23.0 (IBM Corporation, Armonk, NY), and SAS 9.4 (SAS Institute, Cary, NC). Demographic, clinical, and disease characteristics and medication-use variables were individually tested for covariation. Age and the risk score for concurrent medications used were treated as continuous variables. Means and S.D. values were used to describe normally distributed variables, while non-normally distributed variables were described with medians and ranges. All other variables were treated as categorical and collapsed to dichotomous comparisons, as follows: sex (male or female), BMI (normal or not), race (Caucasian or not), reason for admission (medical or surgical), lung disease (yes or no), sleep apnea (none or treated versus untreated), comorbid renal disease (yes or no), and opioid tolerance, as defined by use of ≥60 MME per day over the past 2 weeks (yes or no). Opioids were analyzed by pharmacokinetic profile (e.g., long-acting [LA], short-acting) and route of administration (e.g., oral, patient-controlled analgesia). Morphine use (as-needed use plus use of LA products) was analyzed separately due to the potential for metabolite accumulation and oversedation noted in the literature. Only medication variables with univariate between-group significance (p < 0.10) and sufficiently large cell sizes were used in the extended analysis. Variables of interest were modeled unconditionally. Logistic regression models were then compared for best fit through a variety of covariate selection methods (i.e., purposeful, stepwise, and best subsets). Model adequacy was assessed with the Nagelkerke pseudo R-squared statistic and analysis of the receiver operating characteristic (ROC) curve. Sample size was determined a priori using the estimation method of Tabachnick and Fidell, 16 by which it was calculated that a minimum total sample of 210 would provide sufficient statistical power.
Results
Study sample. A total of 225 patients were included in the study: 75 who experienced oversedation and 150 who did not. The majority of patients were female (60%, n = 135) and/ or Caucasian (84%, n = 190), the mean ± S.D. age was 61 ± 17.9 years (range, 4-94 years), 56% were partnered or married, and the mean ± S.D. BMI was 28.9 ± 7.1 kg/m 2 (range, 14.2-61.0 kg/m 2 ). The median ± S.D. sum of concurrent medications used was 1.3 ± 1.3 medications (range, 0-9 medications). Fifty-five percent of the patients were admitted to the hospital for a surgical reason, 28% had lung disease, and almost 8% were currently experiencing uncontrolled sleep apnea. A full description of patients is provided in Table 1 .
Univariate oversedation results. The majority of the 75 documented oversedation events occurred on day 2 (34.7%, n = 26) or day 3 (22.7%, n = 17) of the hospital stay; most (69.3%, n = 52) occurred during the day shift (7 a.m.-7 p.m.). All potential predictors were individually tested for their relationship with oversedation. The concurrent medications tested (by number and percentage of patients with documented use) included sedating antidepressants (31.1%, n = 70), benzodiazepines (23.1%, n = 52), an- ticonvulsants (20.4%, n = 46), muscle relaxants (16.0%, n = 36), phenothiazines (9.3%, n = 21), antihistamines and antipsychotics (both 8.0%, n = 18), and nonbenzodiazepine hypnotics (2.7%, n = 6), but there were no significance differences in rates of use between oversedated and nonsedated patients. Regarding specific opioid use, over one half of patients (54.7%, n = 123) received LA opioids or continuous infusions, and 38.7% (n = 87) received both LA opioids and as-needed opioids for breakthrough pain. A surgical admission and opioid tolerance were both univariately significant for oversedation but were nonsignificant after controlling for other main effects. Univariate significance was demonstrated for 9 opioid characteristics ( Table 2) . Some of the variables were removed from the final predictive model due to a small number of affected patients (e.g., epidural infusion).
Predictors of oversedation. The final predictive model indicated that female sex, comorbid renal disease, untreated sleep apnea, medication administration via the oral or i.v. push route, and use of LA oxycodone or asneeded hydromorphone were all significant factors in predicting oversedation. The odds of oversedation were 4.2 times higher if a patient had comorbid renal disease, 2.4 times higher if a patient was female, 4.8 times higher if a patient received oxycodone, and 2.7 times higher if a patient received as-needed hydromorphone. Patients who received a medication via the oral and i.v. push routes were, respectively, 84% and 67% less likely to become oversedated. The magnitude of significance of between-group differences is detailed in Table 3 . The final model explained 47.8% of the overall variance in oversedation risk, with the calculated area under the ROC curve (0.86) indicating strong discrimination.
A notable interaction effect of abnormal BMI and untreated sleep apnea was observed. This effect was removed from the final model because no patients with a normal BMI had untreated sleep apnea, which created an unstable model. 17 Additionally, 15 of the 16 patients with untreated sleep apnea (94%) were oversedated. As a result, the unevenly distributed number of patients with untreated sleep apnea accounted for its exceedingly 
Discussion
In our study we sought to identify individual and clinical risk factors for OIRD and oversedation and found that female sex, untreated sleep apnea, comorbid renal disease, and receipt of LA oxycodone or as-needed hydromorphone were all significant predictors of oversedation. Recent literature has indicated that opioids can contribute to oversedation events and that these incidents may be preventable. 8 To our knowledge, our study was the first to identify individual opioids and routes of administration as risk factors for oversedation. As such, forming a predictive model to identify patients who are more susceptive to opioid oversedation is important for patient safety, and the use of such a tool may inform providers who prescribe medications or support staff who monitor hospitalized patients. [18] [19] [20] In previous studies, researchers have attempted to accurately predict oversedation and/or OIRD through analysis of case reports, pharmacy dispensing records (for naloxone administration), and the Anesthesia Closed Claims Project database or analysis of data from nonsurgical, nonfederal acute care facilities across the nation.
5,11-13 Herzig et al. 5 found that severe opioid-related adverse events increased as opioid prescribing increased and that hospitals with higher opioid utilization did not necessarily have more developed safety precautions in place. In some cases, there was a 37% relative difference in opioid prescribing rates between providers. This variation in prescribing practices may have been attributable to a lack of evidence regarding factors that can be used to meaningfully predict oversedation and a lack of screening tools to identify patients at the highest risk. 5, 11, 13 The study of Pawasauskas et al. 12 was the only study we found in the literature that employed a predictive model using case controls to examine risk factors for oversedation in hospitalized patients. While Pawasauskas and colleagues 12 included all oversedated patients who received naloxone to reverse adverse effects of opioid analgesia, our study included only patients who actually responded to naloxone and had demonstrated improvements in sedation symptoms. We also eliminated patients from the analysis if nonmedication causes of oversedation (e.g., sepsis) were identified so that a determination of opioid-induced oversedation was more certain. Interestingly, only comorbid renal disease was a consistent predictor in both our study and that of Pawasauskas et al. Those researchers identified 4 additional predictors: cardiac disease, respiratory disease, concurrent use of CNSsedating medication, and positive smoking status. None of those factors were found to be significant predictors of oversedation risk in our study, possibly due to the use of stricter selection criteria.
Our study found that surgical patients were at increased risk for oversedation and OIRD, but this was demonstrated only in the univariate analysis. Numerous oversedation cases in the surgical patient population have been reported in the literature. 11, 13, [21] [22] [23] This finding is not surprising given that surgical patients experience severe pain and are likely to receive higher levels of opioids. Their predisposition to oversedation relative to medical patients may be due to a combination of sedative medications received from general anesthesia that have shown respiratory depression effects. [24] [25] [26] The type of surgery may also play a role as patients who undergo surgery of the thoracic or abdominal region are well known to experience suboptimal ventilation postoperatively. 27, 28 Opioid tolerance was also significant univariately. No studies were found that reported a relationship between opioid tolerance and oversedation, but it is known that pain can be difficult to manage in this patient population, especially when patients with chronic pain are hospitalized with new acute pain. 29, 30 Lack of knowledge in managing these patients can both interfere with optimal pain management and put them at risk for oversedation. More studies are needed to investigate this relationship.
We found women to be more susceptible to oversedation, but the reason is not clear. Many studies have looked at the difference in pain sensitivities between sexes/genders 31 and recognized the increase in pain sensitivity in women may be due to a combination of biopsychosocial factors, although these study results are mixed. Two meta-analyses that examined 10 years of research on sex differences revealed inconsistent results in hormonal and physiological differences in women, leading to speculation that women have less efficient endogenous pain inhibitory systems. While the influence of psychological factors was also found to be unclear, cognitive and social factors may partly explain differences. 32 Sex-related differences in pain sensitivity are also unclear. 33 Few have assessed the relationships between sex, opioids, and oversedation altogether. 34 In a double-blind randomized controlled trial, sex-related differences and morphine were studied in relationship to ventilator-based effects. 35 These results showed that morphine had no effect on the apneic threshold of women but increased the threshold in men. Also, morphine decreased the hypoxic sensitivity of women but not men. These data support the need to consider sex differences when prescribing opioids. Understanding the interrelationships of opioid use, female sex, metabolism, and pain sensi- tivities in regard to oversedation is an area for further study. In our study, comorbid renal disease was predictive of oversedation, but no specific opioid had an interaction affect with renal disease. It was anticipated that comorbid renal disease and the use of morphine would exhibit a strong interaction due to the retention of the morphine metabolite morphine-6-glucuronide (M6G). It is well documented that patients with renal disease can retain M6G, leading to oversedation and OIRD. 11, [36] [37] [38] [39] Other opioids such as hydromorphone also have active metabolites, but retention with renal compromise and impact on sedation is less clear. The finding that there was no specific opioid-renal disease interaction suggests that clinicians should use opioids cautiously in any patient with comorbid renal disease.
The relationship between increased BMI and obstructive sleep apnea is well known, as is the need for caution when prescribing sedative medications in this patient population. [40] [41] [42] Obesity puts patients at risk for developing hypoventilation syndrome and obstructive sleep apnea, which can cause both daytime and nighttime respiratory depression. 43 In our study, the mean BMI of the 16 patients with untreated sleep apnea was 35 kg/m 2 , and the finding that 15 of 16 patients with untreated sleep apnea had oversedation events was no surprise. In patients with both elevated BMI and obstructive sleep apnea, the prescribing of opioid medicines should put both providers and supportive staff on alert for potential oversedation and respiratory depression. Encouraging patients to bring personal sleep apnea aids to the hospital and to use the equipment while hospitalized, even during daytime naps, is imperative to protect these high-risk patients from oversedation. It is unknown, but likely, that many of the patients in the sample had undiagnosed sleep apnea.
Limitations of this study are noted. The sample size was sufficient according to the power calculation, but some variables could not be analyzed due to small numbers of affected patients. For example, few patients received epidural analgesia, and no patients with a BMI in the normal range had untreated sleep apnea; low or null numbers limited our ability to test some variables, which were thus not included in the final model. In addition, there were wide confidence intervals in the final results, again likely due to low numbers of affected patients. The exclusion criteria, which included EHR documentation of procedures involving moderate sedation and documentation of medication errors, limited the generalizability of our findings; however, we believe that highly specific inclusion criteria allowed for better analytic focus. The sample consisted predominantly of Caucasian and Native American patients hospitalized at a single site, which also limited overall generalizability. Interestingly, while Native Americans constitute about 7% of Montana's population, they were disproportionately represented in the oversedation group (20%, or 15 of 75 patients); this racial difference could be further explored. In addition, the severity of obstructive sleep apnea was not graded. Further research into apnea-hypopnea index values in relation to oversedation risk may be warranted.
Several opportunities for qualityimprovement activities at the study site arose during the study. First, high documented doses of hydromorphone were discovered during the case review; these clearly indicated medication errors, and hydromorphone dose alerts targeting prescribers were subsequently employed. Second, assessments for obstructive sleep apnea were implemented during the study as literature on an associated elevated risk of oversedation emerged.
Conclusion
The study identified 5 risk factors for oversedation and OIRD in hospitalized patients: female sex, untreated sleep apnea, comorbid renal disease, use of LA oxycodone, and as-needed use of hydromorphone.
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